Status:

COMPLETED

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Lead Sponsor:

Soonchunhyang University Hospital

Conditions:

Non-Hodgkin's Lymphoma

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The investigators developed a protocol utilizing once-daily intravenous busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed No...

Detailed Description

Treatment: busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Histologically confirmed aggressive NHL
  • Mantle cell lymphoma
  • salvage chemotherapy sensitive relapse/refractory NHL
  • Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.
  • Age; 18-65
  • Adequate renal function: serum creatinine ≤ 1.5mg/dL
  • Adequate liver functions: Transaminase (AST/ALT) \< 3 X upper normal value \& Bilirubin \< 2 X upper normal value
  • Exclusion criteria
  • low grade NHL
  • Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri
  • Other serious illness or medical conditions
  • Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
  • History of significant neurological or psychiatric disorders
  • Active uncontrolled infection (viral, bacterial or fungal infection)
  • Pregnant or lactating women, women of childbearing potential not employing adequate contraception
  • HIV (+)
  • Patients who have hepatitis B virus (HBV) (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period

Exclusion

    Key Trial Info

    Start Date :

    October 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2013

    Estimated Enrollment :

    51 Patients enrolled

    Trial Details

    Trial ID

    NCT03792815

    Start Date

    October 1 2009

    End Date

    September 1 2013

    Last Update

    January 4 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Soonchunhyang University Hospital

    Seoul, South Korea, 140-743

    Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) | DecenTrialz